arrow
C

Christopher B. Granger

Duke University
H指数:155
被引数:12.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Advancing In-Hospital Mortality Prediction for Acute Myocardial Infarction: an analysis from the American Heart Association Get-With-the-Guidelines Coronary Artery Disease Registry

急性心肌梗死院内死亡风险预测的进展:来自美国心脏协会Get-With-the-Guidelines冠状动脉疾病注册研究的分析

2026-04-140
PRE
Overcoming Barriers to Developing and Implementing Novel Therapies for Hypertension

克服开发与实施新型高血压疗法的障碍

2025-10-010
PRE
Cost-effectiveness of apixaban vs. aspirin for the reduction of thrombo-embolism in high-risk patients with device-detected atrial fibrillation: insights from the ARTESiA trial

阿哌沙班与阿司匹林在降低设备检测到心房颤动的高危患者血栓栓塞事件中的成本效益:ARTESiA试验的启示

2025-09-011
OAAI
Apixaban for stroke prevention in subclinical atrial fibrillation detected by an implantable cardiac monitor: a subgroup analysis of ARTESiA

阿哌沙班用于由植入式心脏监护仪检测到的亚临床房颤患者的卒中预防:ARTESiA研究的亚组分析

2025-08-050
PRE
Characteristics of patients prescribed SGLT-2i and/or GLP-1RA among cardiology clinics in the US: insights from the COORDINATE-Diabetes trial

美国心脏病诊所开具SGLT-2i和/或GLP-1RA处方的患者特征:来自COORDINATE-Diabetes试验的见解

2025-07-230
OAAI
Atrial Fibrillation Progression in Patients with Device-Detected Subclinical Atrial Fibrillation: Insights from the ARTESiA Trial

设备检测到的亚临床心房颤动患者中心房颤动进展:ARTESiA试验的见解

2025-07-090
PRE
Sex-related differences in long-term quality of life after out-of-hospital cardiac arrest: a nationwide cross-sectional survey study

院外心脏骤停后长期生活质量中的性别相关差异:一项全国性横断面调查研究

2025-07-011
PRE
Corrigendum to “Effects of dialysate potassium concentration of 3.0 mmol/l with sodium zirconium cyclosilicate on dialysis-free days versus dialysate potassium concentration of 2.0 mmol/l alone on rates of cardiac arrhythmias in hemodialysis patients with hyperkalemia.” Kidney International 2025;107:169–179

勘误:“3.0 mmol/l透析液钾浓度与锆基环硅酸盐相比,在无透析日对高钾血症血液透析患者心律失常发生率的影响,以及2.0 mmol/l透析液钾浓度单独使用对心律失常发生率的影响。”《肾脏国际杂志》2025;107:169–179

2025-05-200
OA
Advancement of the implementation of evidence-based therapies for cardiovascular-kidney-metabolic conditions: A multi-stakeholder perspective

心血管-肾脏-代谢疾病循证疗法的实施进展:多利益相关方视角

2025-05-070
PRE
Pre-treatment lysis time of plasma-derived fibrin clots and bleeding in patients on oral anticoagulants for atrial fibrillation in the ARISTOTLE trial

ARISTOTLE试验中,房颤患者口服抗凝药物治疗期间,血浆源性纤维蛋白凝块的前处理裂解时间与出血情况。

2025-05-011
OAAI
Di scontinuation of SGLT-2i and GLP-1RA among persons with Type 2 diabetes and atherosclerotic cardiovascular disease treated in US cardiology clinics

在美国心脏病诊所治疗的2型糖尿病和动脉粥样硬化性心血管疾病患者中继续SGLT-2i和GLP-1RA

2025-04-010
PRE